14 февр. 2008 г. · Conclusions: A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to ... |
14 февр. 2008 г. · A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long- ... |
Since the publication of the HERMES and OLYMPUS trials, rituximab has been increasingly used off-label to treat MS in Sweden, in progressive MS with signs of ... |
8 янв. 2021 г. · Two randomized placebo-controlled phase 2 trials, the “Helping to Evaluate Rituxan in Relapsing–Remitting Multiple Sclerosis (HERMES)” and “A ... |
14 февр. 2008 г. · A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. |
Two phase-2/3 clinical trials (HERMES and OLYMPUS) illustrated the potential efficacy of rituximab in relapsing-remitting MS (RRMS) and inflammatory primary ... |
12 июн. 2023 г. · Rituximab was not noninferior to ocrelizumab, and rituximab treatment was associated with a higher rate and risk of relapse. |
12 нояб. 2018 г. · Rituximab was well-tolerated and effective in reducing relapse rate and stabilizing disease in relapsing-remitting and progressive MS patients. |
22 окт. 2024 г. · We therefore examined the safety and efficacy of rituximab compared with dimethyl fumarate in patients with relapsing-remitting multiple ... |
| Novbeti > |
| Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |